Phase 2 Start

ATOS: Phase2_Start: A Phase 2 Open-Label, Safety, Tolerability and Exposure Study of Oral (Z)-Endoxifen for the Treatment of Gonadotropin-Independent Precocious Puberty in Girls With McCune-Albright Syndrome

Name: Phase2_Start: A Phase 2 Open-Label, Safety, Tolerability and Exposure Study of Oral (Z)-Endoxifen for the Treatment of Gonadotropin-Independent Precocious Puberty in Girls With McCune-Albright Syndrome
Start: 2027-03-01
End: 2027-03-01

March 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 1, 2027
Company: ATOSSA THERAPEUTICS, INC. (ATOS)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start

Phase2_Start: A Phase 2 Open-Label, Safety, Tolerability and Exposure Study of Oral (Z)-Endoxifen for the Treatment of Gonadotropin-Independent Precocious Puberty in Girls With McCune-Albright Syndrome

March 1, 2027

ATOS overview →

Company: ATOSSA THERAPEUTICS, INC. (ATOS)